Frontiers in Neurology (Apr 2019)
Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease
- Tracy R. Melzer,
- Tracy R. Melzer,
- Tracy R. Melzer,
- Megan R. Stark,
- Megan R. Stark,
- Ross J. Keenan,
- Ross J. Keenan,
- Daniel J. Myall,
- Michael R. MacAskill,
- Michael R. MacAskill,
- Toni L. Pitcher,
- Toni L. Pitcher,
- Toni L. Pitcher,
- Leslie Livingston,
- Leslie Livingston,
- Sophie Grenfell,
- Kyla-Louise Horne,
- Kyla-Louise Horne,
- Bob N. Young,
- Maddie J. Pascoe,
- Mustafa M. Almuqbel,
- Mustafa M. Almuqbel,
- Mustafa M. Almuqbel,
- Jian Wang,
- Steven H. Marsh,
- David H. Miller,
- David H. Miller,
- David H. Miller,
- John C. Dalrymple-Alford,
- John C. Dalrymple-Alford,
- John C. Dalrymple-Alford,
- John C. Dalrymple-Alford,
- Tim J. Anderson,
- Tim J. Anderson,
- Tim J. Anderson,
- Tim J. Anderson
Affiliations
- Tracy R. Melzer
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Tracy R. Melzer
- Department of Medicine, University of Otago, Christchurch, New Zealand
- Tracy R. Melzer
- Brain Research New Zealand Rangahau Roro Aotearoa Centre of Research Excellence, Christchurch, New Zealand
- Megan R. Stark
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Megan R. Stark
- Department of Medicine, University of Otago, Christchurch, New Zealand
- Ross J. Keenan
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Ross J. Keenan
- Pacific Radiology Group, Christchurch, New Zealand
- Daniel J. Myall
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Michael R. MacAskill
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Michael R. MacAskill
- Department of Medicine, University of Otago, Christchurch, New Zealand
- Toni L. Pitcher
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Toni L. Pitcher
- Department of Medicine, University of Otago, Christchurch, New Zealand
- Toni L. Pitcher
- Brain Research New Zealand Rangahau Roro Aotearoa Centre of Research Excellence, Christchurch, New Zealand
- Leslie Livingston
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Leslie Livingston
- Department of Medicine, University of Otago, Christchurch, New Zealand
- Sophie Grenfell
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Kyla-Louise Horne
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Kyla-Louise Horne
- Department of Medicine, University of Otago, Christchurch, New Zealand
- Bob N. Young
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Maddie J. Pascoe
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Mustafa M. Almuqbel
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Mustafa M. Almuqbel
- Department of Medicine, University of Otago, Christchurch, New Zealand
- Mustafa M. Almuqbel
- Pacific Radiology Group, Christchurch, New Zealand
- Jian Wang
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
- Steven H. Marsh
- Department of Physics and Astronomy, University of Canterbury, Christchurch, New Zealand
- David H. Miller
- New Zealand Brain Research Institute, Christchurch, New Zealand
- David H. Miller
- Department of Medicine, University of Otago, Christchurch, New Zealand
- David H. Miller
- Institute of Neurology, University College London, London, United Kingdom
- John C. Dalrymple-Alford
- New Zealand Brain Research Institute, Christchurch, New Zealand
- John C. Dalrymple-Alford
- Department of Medicine, University of Otago, Christchurch, New Zealand
- John C. Dalrymple-Alford
- Brain Research New Zealand Rangahau Roro Aotearoa Centre of Research Excellence, Christchurch, New Zealand
- John C. Dalrymple-Alford
- Department of Psychology, University of Canterbury, Christchurch, New Zealand
- Tim J. Anderson
- New Zealand Brain Research Institute, Christchurch, New Zealand
- Tim J. Anderson
- Department of Medicine, University of Otago, Christchurch, New Zealand
- Tim J. Anderson
- Brain Research New Zealand Rangahau Roro Aotearoa Centre of Research Excellence, Christchurch, New Zealand
- Tim J. Anderson
- Department of Neurology, Christchurch Hospital, Christchurch, New Zealand
- DOI
- https://doi.org/10.3389/fneur.2019.00391
- Journal volume & issue
-
Vol. 10
Abstract
The extent to which Alzheimer neuropathology, particularly the accumulation of misfolded beta-amyloid, contributes to cognitive decline and dementia in Parkinson's disease (PD) is unresolved. Here, we used Florbetaben PET imaging to test for any association between cerebral amyloid deposition and cognitive impairment in PD, in a sample enriched for cases with mild cognitive impairment. This cross-sectional study used Movement Disorders Society level II criteria to classify 115 participants with PD as having normal cognition (PDN, n = 23), mild cognitive impairment (PD-MCI, n = 76), or dementia (PDD, n = 16). We acquired 18F-Florbetaben (FBB) amyloid PET and structural MRI. Amyloid deposition was assessed between the three cognitive groups, and also across the whole sample using continuous measures of both global cognitive status and average performance in memory domain tests. Outcomes were cortical FBB uptake, expressed in centiloids and as standardized uptake value ratios (SUVR) using the Centiloid Project whole cerebellum region as a reference, and regional SUVR measurements. FBB binding was higher in PDD, but this difference did not survive adjustment for the older age of the PDD group. We established a suitable centiloid cut-off for amyloid positivity in Parkinson's disease (31.3), but there was no association of FBB binding with global cognitive or memory scores. The failure to find an association between PET amyloid deposition and cognitive impairment in a moderately large sample, particularly given that it was enriched with PD-MCI patients at risk of dementia, suggests that amyloid pathology is not the primary driver of cognitive impairment and dementia in most patients with PD.
Keywords
